| ²é¿´: 186 | »Ø¸´: 0 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
lwjxzľ³æÖ®Íõ (ÖªÃû×÷¼Ò)
|
[×ÊÔ´]
¡¾×ªÌû¡¿PICS³ö°æÖ´ÐÐÖÊÁ¿·çÏÕ¹ÜÀíµÄ·½·¨Ñ§Ê¾ÀýÎļþ2010.01
|
||
|
Ó¢Îİæ Îļþ·ÖËĸö²¿·Ö£º ½éÉÜ£¬ ·½·¨Ñ§ÃèÊö£¬ ·½·¨Ñ§Ö´ÐС¢ ·½·¨Ñ§°²ÅÅ¡£ Quality Risk Management Implementation of ICH Q9 in the pharmaceutical field an example of methodology from PIC/S Document > Authors: L. Viornery (AFSSAPS) Ph. Le Goff (H&LG Consultants) > Date: Jan. 04,2010 > Reference: H5PCS4122J_QRM_pLHntsJ493r1A0_method > Version: r1A0 Content 1. Introduction.......................................................................2 2. Description of the methodology ....................................3 2.1. Objective of the Quality Risk Management..........3 2.2. General approach..........................................4 2.3. Description of QRM methodology....................6 2.3.1. Preamble..............................6 2.3.2. Design of methodology ......................7 2.3.3. Input and output..............................9 2.3.4. Dissociating approach.........................11 2.3.5. Quantification......................15 3. Implementation of methodology.........................19 3.1. Determination of the systemic risk ...................19 3.2. Product factor ..................................27 3.3. Determination of the total risk ......................28 4. Deployment of methodology ........................29 * Previously issued in a simplified version as PS/INF 20/2009 ÏÂÔØ£ºhttp://ishare.iask.sina.com.cn/f/6747798.html http://ishare.iask.sina.com.cn/f/6747798.html |
» ²ÂÄãϲ»¶
¸ßЧ·Î°ÐÏòRNAתȾ£¬¼ÓËٷβ¿RNAÒ©Î↑·¢
ÒѾÓÐ2È˻ظ´
¶þÌǵÄÌÇÖ¬£¬ºÏ³Éºósephadex LH-20·ÖÀë²»³öÀ´£¬ÇóÖú
ÒѾÓÐ1È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ57È˻ظ´
ÄÏ·½Ò½¿Æ´óѧÖé½Ò½ÔºÐ¤¼ÆÉú¿ÎÌâ×éÕÐÊÕ²©Ê¿Éú £¨2026ÄêÈëѧ£©
ÒѾÓÐ2È˻ظ´
349ҩѧר˶105500Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ1È˻ظ´
298Çóµ÷¼ÁÒ»Ö¾Ô¸Öк£Ñó
ÒѾÓÐ3È˻ظ´
ҩѧµ÷¼ÁÉêÇë×Ô¼öÐÅ£¬Ò»Ö¾Ô¸ÖÐÄÏ´óѧ
ÒѾÓÐ1È˻ظ´
ҩѧ349ר˶Çóµ÷¼Á
ÒѾÓÐ1È˻ظ´
¡¶×óÒÒÀÎ÷̹עÉäÒºÖÆ±¸¹¤ÒÕÑо¿¡¢ÖÊÁ¿¿ØÖƺÍÎȶ¨ÐÔÑо¿¡·ÏÂÔØ
ÒѾÓÐ1È˻ظ´
105500ҩѧÇóµ÷¼Á£¬Ò»Ö¾Ô¸É½¶«´óѧҩѧ£¬348·Ö
ÒѾÓÐ1È˻ظ´














»Ø¸´´ËÂ¥